8-K: CervoMed's Neflamapimod Shows Sustained Efficacy in Dementia with Lewy Bodies Trial

CervoMed Inc. announced positive 32-week data from the RewinD-LB trial extension phase, demonstrating neflamapimod's sustained effect on slowing clinical progression and reducing a key neurodegeneration biomarker in patients with Dementia with Lewy Bodies.

Summary

• Neflamapimod treatment resulted in a 54% risk reduction in clinically significant worsening based on the Clinical Dementia Rating Sum of Boxes (CDR-SB) at Week 32 (p=0.0037).
• This risk reduction improved to 64% (p=0.0001) among patients with minimal evidence of Alzheimer's Disease (AD) co-pathology (ptau181 < 2.2 pg/mL at screening).
• Patients treated with neflamapimod demonstrated a statistically significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP) at Week 32 of the Extension phase (p<0.0001).
• An older batch of neflamapimod capsules ('Old Capsules') was associated with plasma exposures below the expected range, while a new batch ('New Capsules') achieved target concentrations and showed statistically significant clinical benefit.
• The established ptau181 cutoff of 2.2 pg/mL for AD appears to be the optimal cutoff to maximize neflamapimod treatment response in DLB patients.
• There is 92% concordance for presence or absence of AD co-pathology between published cutoffs for plasma ptau217 (0.63 pg/mL) and ptau181 (2.2 pg/mL), with a strong correlation (r=0.81, p<0.001).
• Previously presented 16-week data showed improvement on CDR-SB with 'New Capsules' compared to 'Old Capsules' (p<0.001) and placebo (p=0.003).
• A 40% lower relative incidence of clinically meaningful worsening was observed in 'New Capsule' recipients compared to 'Old Capsule' recipients during the first 16 weeks, improving to 62% lower in participants with screening plasma ptau181 < 2.2 pg/mL.
• Statistically significant improvement on Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC) was observed with 'New Capsules' compared to 'Old Capsules' (p=0.035) and placebo (p=0.039).
• Both 'Old' and 'New Capsules' demonstrated comparable tolerability profiles with no new safety signals identified.
• A lower incidence of falls was seen in participants with screening ptau181 < 2.2 pg/mL who received 'New Capsules' compared to 'Old Capsules' (p=0.025) or placebo (p=0.007).

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical trial data for neflamapimod in DLB, showing significant efficacy in slowing disease progression and impacting a key neurodegeneration biomarker. The results are described as 'unprecedented' and 'potentially transformative' by management, bolstering confidence for a Phase 3 trial. The only minor negative is the past issue with 'Old Capsules', which has been resolved with 'New Capsules' showing strong results. The overall outlook is very optimistic for the drug's potential.

Positives

• Neflamapimod demonstrated a 54% risk reduction in clinically significant worsening (CDR-SB) at Week 32 (p=0.0037).
• The risk reduction improved to 64% (p=0.0001) in patients with minimal AD co-pathology (ptau181 < 2.2 pg/mL).
• A statistically significant reduction in plasma levels of glial fibrillary acidic protein (GFAP), a key biomarker of neurodegeneration, was observed at Week 32 (p<0.0001).
• The 'New Capsules' of neflamapimod achieved target plasma concentrations and showed statistically significant clinical benefit.
• Strong concordance (92%) and correlation (r=0.81, p<0.001) between ptau181 and ptau217 biomarkers for identifying AD co-pathology.
• Neflamapimod demonstrated comparable tolerability and no new safety signals during the Extension phase.
• A lower incidence of falls was observed in participants receiving 'New Capsules' with ptau181 < 2.2 pg/mL.
• The RewinD-LB trial is primarily funded by a $21.3 million grant from the National Institutes of Health's National Institute on Aging.

Negatives

• An older batch of neflamapimod capsules ('Old Capsules') used during the double-blind phase and part of the Extension phase was associated with plasma exposures below the expected and targeted range.
• All analyses reported are exploratory in nature, though p-values and statistical significance are provided.

Risks

• The Company's available cash resources and the availability of additional funds on acceptable terms.
• The results of the Company's clinical trials, including RewinD-LB, may not be replicated in later trials.
• The likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA.
• The ability to implement business plans, forecasts, and other expectations in the future.
• General economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts.
• Other factors discussed under the heading Risk Factors in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

The company plans to initiate a Phase 3 trial for neflamapimod in DLB and expects to meet with the U.S. Food and Drug Administration in the fourth quarter of 2025 to align on the trial design. They remain deeply committed to delivering a meaningful treatment option for underserved DLB patients and their families. The level of effect observed, if confirmed in a Phase 3 pivotal trial, would represent an important advance in the unmet treatment needs of patients with DLB.

Management Comments

• "We are thrilled by these unprecedented data demonstrating a 54% reduction in risk of clinically significant worsening on the CDR-SB over 32 weeks of treatment, improving to 64% when applying the more stringent ptau181 threshold to define DLB without Alzheimers Disease (AD) copathology underscoring neflamapimods potential to have a powerful impact on CDRSB, a gold standard measure of clinical progression in dementia trials." John Alam, MD, Co-Principal Investigator of the RewinD-LB trial and CEO of CervoMed.
• "Combined with the positive effects on a robust blood-based biomarker of the underlying neurodegenerative process, these results bolster our confidence as we progress towards initiating a Phase 3 trial and prepare to meet with the U.S. Food and Drug Administration in the fourth quarter of 2025 to align on the trial design. We remain deeply committed to delivering a meaningful treatment option for underserved DLB patients and their families." John Alam, MD.
• "These new data are potentially transformative with respect to our understanding of the potential of neflamapimod in the treatment of DLB." Lawrence S. Honig, MD, PhD, Professor of Neurology at Columbia University Irving Medical Center.
• "Reducing the risk of a 1.5-point worsening over 32 weeks on the CDRSB by more than 50% would likely represent a clinically meaningful slowing of clinical progression at a level that patients and caregivers would notice in daytoday function. This level of effect, if confirmed in a Phase 3 pivotal trial, would be an important advance in the unmet treatment needs of patients with DLB, the second most common dementia, which is a challenging disease, due to its involvement of both movement and cognition, and due to the lack of effective current treatments." Lawrence S. Honig, MD, PhD.

Industry Context

Dementia with Lewy Bodies (DLB) is the second most common dementia, characterized by both movement and cognitive challenges, and currently lacks effective treatments. Neflamapimod, by inhibiting p38 mitogen-activated protein kinase alpha, targets synaptic dysfunction, a reversible aspect of neurodegenerative processes. The positive results, especially the significant reduction in clinical worsening and impact on a neurodegeneration biomarker, position neflamapimod as a potentially important advance in an area with high unmet medical need, distinguishing it from treatments for pure Alzheimer's Disease by focusing on DLB patients without significant AD co-pathology.

Comparison to Industry Standards

• The CDR-SB (Clinical Dementia Rating Sum of Boxes) is described as a 'gold standard measure of clinical progression in dementia trials,' indicating that the trial's primary endpoint aligns with widely accepted industry metrics for evaluating dementia treatments.
• The ptau181 and ptau217 biomarkers are validated for AD, and their strong concordance (92%) and correlation (r=0.81, p<0.001) in identifying AD co-pathology in DLB patients suggest CervoMed is utilizing established and reliable methods for patient stratification, similar to approaches seen in broader Alzheimer's research.
• The stated 'more than 50% reduction' in risk of a 1.5-point worsening on CDR-SB over 32 weeks is highlighted as 'clinically meaningful' and potentially noticeable by patients and caregivers, suggesting a level of efficacy that would be considered significant in the context of neurodegenerative disease trials where even modest slowing of progression is highly valued.
• The lack of effective current treatments for DLB positions neflamapimod's potential as a significant advancement in an area of high unmet medical need, contrasting with the more crowded and often less successful landscape of Alzheimer's drug development.

Stakeholder Impact

• Shareholders: Highly positive clinical trial results could significantly increase shareholder value due to the potential for a breakthrough treatment in a high-unmet-need disease. The mention of future funding needs for Phase 3 could imply potential dilution, but the positive data likely outweighs this.
• Patients with DLB and their families: The data suggests a clinically meaningful slowing of disease progression, offering significant hope for a new, effective treatment option for a challenging disease with limited current therapies.
• Healthcare Providers/Researchers: The data, especially regarding biomarkers and patient stratification, could influence diagnostic and treatment approaches for DLB.
• Regulatory Authorities (FDA): The company plans to meet with the FDA in Q4 2025, indicating active engagement towards potential regulatory approval.

Next Steps

• Initiating a Phase 3 trial for neflamapimod in DLB.
• Meeting with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025 to align on the Phase 3 trial design.
• Disbursement of the $21.3 million NIH grant over the course of the trial as costs are incurred.
• Potential acquisition of sufficient funding for any Phase 3 trial.

Key Dates

Recommendation

The 32-week data from the RewinD-LB trial extension phase for neflamapimod in Dementia with Lewy Bodies (DLB) is exceptionally positive, demonstrating a 54% to 64% risk reduction in clinically significant worsening and a significant reduction in a key neurodegeneration biomarker. These results are described as "unprecedented" and "potentially transformative" by experts, addressing a disease with high unmet medical need. The successful resolution of the "Old Capsules" issue and the clear efficacy of the "New Capsules" de-risk the program significantly. While a Phase 3 trial and associated funding needs are next steps, the strength of these Phase 2b results strongly positions CervoMed for future success and potential market leadership in DLB treatment, making it a compelling "strong buy" for investors seeking exposure to innovative neurological therapies.

Keywords

CervoMed, CRVO, Neflamapimod, Dementia with Lewy Bodies, DLB, Neurodegeneration, Clinical Trial, Phase 2b, RewinD-LB, CDR-SB, GFAP, ptau181, Alzheimer's Disease, Biomarker, Clinical Progression, Neurologic Disorders, Drug Development, Biotechnology, Pharmaceuticals